trending Market Intelligence /marketintelligence/en/news-insights/trending/S0nrch_aeGjcZ_TXbTvr7A2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

GlaxoSmithKline wins patent suit against Vectura in UK court


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

GlaxoSmithKline wins patent suit against Vectura in UK court

Vectura Group PLC said a U.K. court voted in favor of GlaxoSmithKline PLC relating to a dispute on an agreement between the two companies.

The litigation pertains to certain additional patents under an August 2010 patent license and option agreement with GlaxoSmithKline.

U.K.-based Vectura said it was evaluating a future course of action, including an option to appeal, with its advisers.

Vectura expects the results of the U.K. lawsuits will not materially affect its other cases pending against GlaxoSmithKline in the U.S.

Vectura, which develops and markets products for airways-related diseases, had signed an agreement with Hikma Pharmaceuticals PLC in November to develop and commercialize generic versions of GlaxoSmithKline's Ellipta portfolio of respiratory therapies.